Adell Harriman & Carpenter Inc. Has $4.77 Million Stake in iShares NASDAQ Biotechnology Index (IBB)

Adell Harriman & Carpenter Inc. lifted its stake in shares of iShares NASDAQ Biotechnology Index (NASDAQ:IBB) by 203.1% in the 4th quarter, Holdings Channel reports. The firm owned 44,669 shares of the financial services provider’s stock after buying an additional 29,931 shares during the quarter. Adell Harriman & Carpenter Inc.’s holdings in iShares NASDAQ Biotechnology Index were worth $4,769,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently added to or reduced their stakes in IBB. Parametric Portfolio Associates LLC raised its stake in shares of iShares NASDAQ Biotechnology Index by 8.7% during the second quarter. Parametric Portfolio Associates LLC now owns 988 shares of the financial services provider’s stock worth $306,000 after purchasing an additional 79 shares during the last quarter. Security National Bank of Sioux City Iowa IA raised its position in iShares NASDAQ Biotechnology Index by 0.9% in the second quarter. Security National Bank of Sioux City Iowa IA now owns 2,981 shares of the financial services provider’s stock worth $925,000 after acquiring an additional 27 shares in the last quarter. Psagot Investment House Ltd. raised its position in iShares NASDAQ Biotechnology Index by 1.4% in the second quarter. Psagot Investment House Ltd. now owns 52,476 shares of the financial services provider’s stock worth $16,272,000 after acquiring an additional 708 shares in the last quarter. Martin & Co. Inc. TN raised its position in iShares NASDAQ Biotechnology Index by 3.5% in the second quarter. Martin & Co. Inc. TN now owns 10,970 shares of the financial services provider’s stock worth $3,402,000 after acquiring an additional 375 shares in the last quarter. Finally, Altavista Wealth Management Inc. raised its position in iShares NASDAQ Biotechnology Index by 8.2% in the second quarter. Altavista Wealth Management Inc. now owns 6,118 shares of the financial services provider’s stock worth $1,897,000 after acquiring an additional 465 shares in the last quarter. Institutional investors and hedge funds own 25.01% of the company’s stock.

iShares NASDAQ Biotechnology Index (NASDAQ:IBB) opened at $107.18 on Tuesday. The stock has a market capitalization of $9,800.00, a price-to-earnings ratio of 3.54 and a beta of 1.37. iShares NASDAQ Biotechnology Index has a 52-week low of $92.77 and a 52-week high of $119.30.

COPYRIGHT VIOLATION WARNING: This story was reported by Stock Observer and is the property of of Stock Observer. If you are viewing this story on another website, it was stolen and reposted in violation of international trademark & copyright laws. The legal version of this story can be accessed at https://www.thestockobserver.com/2018/02/06/adell-harriman-carpenter-inc-has-4-77-million-stake-in-ishares-nasdaq-biotechnology-index-ibb.html.

About iShares NASDAQ Biotechnology Index

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.

Want to see what other hedge funds are holding IBB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares NASDAQ Biotechnology Index (NASDAQ:IBB).

Institutional Ownership by Quarter for iShares NASDAQ Biotechnology Index (NASDAQ:IBB)

Receive News & Ratings for iShares NASDAQ Biotechnology Index Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares NASDAQ Biotechnology Index and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply